Top 10 Penny Stocks That Will Skyrocket

2. Geron Corporation (NASDAQ:GERN) 

Price: $1.82

Analyst Upside Potential: 147.25%

Number of Hedge Fund Holders: 44

Geron Corporation (NASDAQ:GERN) is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapeutic products for cancer, specifically hematologic malignancies. Its primary focus is on the development of imetelstat, an investigational first-in-class telomerase inhibitor.

The fiscal 2024 was a significant year for the company, particularly with the development and commercialization of RYTELO. RYTELO is Geron Corporation’s (NASDAQ:GERN) first-in-class telomerase inhibitor for hematologic malignancies. It was approved by the FDA in June 2024 for treating certain lower-risk myelodysplastic syndromes. Moreover, in August 2024, RYTELO gained favorable placement in the NCCN guidelines, receiving a Category 1 treatment recommendation for second-line RS-positive and RS-negative patients. Since its launch in the US at the end of June 2024, RYTELO achieved $76.5 million in net product revenue by year-end, surpassing internal expectations.

Moreover, on March 12, Robert Driscoll from Wedbush maintained a Buy rating on the stock, with a price target of $7.00. It is one of the top penny stocks that will skyrocket as analysts expect more than 147% upside.